Barclays PLC Adaptive Biotechnologies Corp Transaction History

Barclays PLC

$436 Billion
Q2 2025

A detailed history of Barclays PLC transactions in Adaptive Biotechnologies Corp stock. As of the latest transaction made, Barclays PLC holds 362,634 shares of ADPT stock, worth $6.47 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

362,634

Previous 362,634 -0.0%

Holding current value

$6.47 Million

Previous $4.22 Million -0.0%

% of portfolio

0.0%

Previous 0.0%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 13, 2025	BUY	$6.83 - $12.16 $1.08 Million - $1.93 Million	158,664 Added 77.79%	362,634 $4.22 Million
Q1 2025 May 15, 2025	SELL	$6.07 - $8.66 $376,922 - $537,751	-62,096 Reduced 23.34%	203,970 $1.52 Million
Q4 2024 Feb 13, 2025	BUY	$4.37 - $6.78 $156,834 - $243,327	35,889 Added 15.59%	266,066 $1.6 Million
Q3 2024 Nov 15, 2024	BUY	$3.37 - $5.12 $464,844 - $706,232	137,936 Added 149.54%	230,177 $1.18 Million
Q2 2024 Aug 14, 2024	SELL	$2.34 - $3.96 $138,677 - $234,685	-59,264 Reduced 39.12%	92,241 $333,000
Q1 2024 May 15, 2024	SELL	$2.88 - $4.8 $219,888 - $366,480	-76,350 Reduced 33.51%	151,505 $486,000
Q4 2023 Feb 15, 2024	BUY	$3.46 - $5.33 $317,745 - $489,475	91,834 Added 67.51%	227,855 $1.12 Million
Q3 2023 Nov 07, 2023	BUY	$5.07 - $8.44 $56,337 - $93,785	11,112 Added 8.9%	136,021 $741,000
Q2 2023 Aug 03, 2023	SELL	$6.19 - $8.78 $479,848 - $680,625	-77,520 Reduced 38.29%	124,909 $838,000
Q1 2023 May 04, 2023	SELL	$7.8 - $10.11 $3.09 Million - $4 Million	-396,135 Reduced 66.18%	202,429 $1.79 Million
Q4 2022 Feb 13, 2023	BUY	$6.26 - $9.34 $2.75 Million - $4.11 Million	439,726 Added 276.84%	598,564 $4.57 Million
Q3 2022 Nov 03, 2022	BUY	$6.5 - $12.67 $553,273 - $1.08 Million	85,119 Added 115.46%	158,838 $1.13 Million
Q2 2022 Aug 12, 2022	BUY	$6.4 - $14.73 $225,766 - $519,615	35,276 Added 91.76%	73,719 $596,000
Q1 2022 May 16, 2022	SELL	$10.12 - $28.9 $3.01 Million - $8.59 Million	-297,365 Reduced 88.55%	38,443 $534,000
Q4 2021 Feb 14, 2022	BUY	$25.17 - $36.85 $7.45 Million - $10.9 Million	296,137 Added 746.48%	335,808 $9.42 Million
Q3 2021 Nov 09, 2021	BUY	$30.02 - $39.87 $495,299 - $657,815	16,499 Added 71.2%	39,671 $1.35 Million
Q2 2021 Aug 13, 2021	SELL	$32.22 - $44.59 $1.48 Million - $2.05 Million	-45,918 Reduced 66.46%	23,172 $947,000
Q1 2021 May 13, 2021	SELL	$37.26 - $67.74 $1.22 Million - $2.23 Million	-32,850 Reduced 32.22%	69,090 $2.78 Million
Q4 2020 Feb 11, 2021	BUY	$45.01 - $65.47 $4.58 Million - $6.67 Million	101,852 Added 115740.91%	101,940 $6.03 Million
Q3 2020 Nov 12, 2020	SELL	$35.79 - $48.81 $836,805 - $1.14 Million	-23,381 Reduced 99.63%	88 $4,000
Q2 2020 Aug 12, 2020	BUY	$24.95 - $48.38 $537,423 - $1.04 Million	21,540 Added 1116.64%	23,469 $1.14 Million
Q1 2020 May 13, 2020	BUY	$16.96 - $34.16 $27,526 - $55,441	1,623 Added 530.39%	1,929 $54,000
Q4 2019 Feb 10, 2020	SELL	$24.56 - $32.8 $144,904 - $193,519	-5,900 Reduced 95.07%	306 $9,000
Q3 2019 Nov 14, 2019	SELL	$30.31 - $53.51 $246,268 - $434,768	-8,125 Reduced 56.7%	6,206 $191,000
Q2 2019 Aug 14, 2019	BUY	$40.3 - $48.3 $577,539 - $692,187	14,331 New	14,331 $693,000

Others Institutions Holding ADPT

# of Institutions

267

Shares Held

149M

Call Options Held

168K

Put Options Held

25.2K

View Full List

About Adaptive Biotechnologies Corp

Ticker ADPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 142,872,992
Market Cap $2.55B
Description
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signal...

More about ADPT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account